Suheung Valuation

Q: What is the Fair Price of A008490 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

A008490 (₩13110) is trading above our estimate of [[fair value]] (₩2211.64)

Is A008490 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A008490 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: A008490 (₩13110) is trading above our estimate of fair value (₩2211.64)

Significantly Below Fair Value: A008490 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A008490?

Key metric: As A008490 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for A008490. This is calculated by dividing A008490's market cap by their current earnings.
What is A008490's PE Ratio?
PE Ratio	82x
Earnings	₩1.78b
Market Cap	₩145.77b

A008490 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	0.9x
Enterprise Value/EBITDA	7.9x
PEG Ratio	4.3x

Price to Earnings Ratio vs Peers

How does A008490's PE Ratio compare to its peers?

The above table shows the PE ratio for A008490 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	30.7x
A100700 Sewoon Medical	8x	n/a	₩113.0b
A131030 OPTUS Pharmaceutical	8.6x	n/a	₩88.2b
A142280 Green Cross Medical Science	69.8x	n/a	₩82.1b
A450330 HASS	36.4x	n/a	₩61.4b
A008490 Suheung	82x	18.9%	₩145.8b

Price-To-Earnings vs Peers: A008490 is expensive based on its Price-To-Earnings Ratio (82x) compared to the peer average (30.7x).

Price to Earnings Ratio vs Industry

How does A008490's PE Ratio compare vs other companies in the KR Medical Equipment Industry?

1 Company	Price / Earnings	Estimated Growth	Market Cap
A035610 Solborn	2.6x	n/a	US$68.56m

No more companies available in this PE range

1 Company		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: A008490 is expensive based on its Price-To-Earnings Ratio (82x) compared to the KR Medical Equipment industry average (13.8x).

Price to Earnings Ratio vs Fair Ratio

What is A008490's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A008490 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	82x
Fair PE Ratio	12x

Price-To-Earnings vs Fair Ratio: A008490 is expensive based on its Price-To-Earnings Ratio (82x) compared to the estimated Fair Price-To-Earnings Ratio (12x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Access Bio

₩189.3b

Engages in the research, development, and manufacture of in vitro rapid diagnostic tests, biosensors, and molecular diagnostic products worldwide.

A950130

₩5,600.00

0.2%

-38.9%

Wonbiogen

₩44.8b

Develops and sells medical equipment in South Korea.

A307280

₩1,262.00

1.9%

-18.7%

Boditech Med

₩356.7b

Offers instruments and diagnostic reagents in South Korea and internationally.

A206640

₩16,230.00

1.3%

-5.0%